治験レーダーAI | ||
|---|---|---|
治験 NCT07439965 (DBCR-EV-p)（対象：Subarachnoid Aneurysm Hemorrhage、破裂していない頭蓋内動脈瘤）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions (DBCR-EV-p) 120 バイオマーカー 観察研究
治験（臨床試験）の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします！「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT07439965 (DBCR-EV-p) は 観察研究 臨床試験 で、Subarachnoid Aneurysm Hemorrhage、破裂していない頭蓋内動脈瘤 に関するものです。現在は 募集中 で、2025年7月29日 から開始しています。120 名の参加者 の募集が計画されています。この試験は The First Hospital of Jilin University によって主導され、2026年6月1日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年2月27日 です。
概要
The goal of this observational study is to learn about the protein heterogeneity in extracellular vesicles (EVs) derived from different human blood circulatory regions of patients with ruptured or unruptured intracranial aneurysms. The main objectives are:
Reveal the proteomic heterogeneity of EVs in different blood circulatory regions of the human body。 Reveal the proteomic differences of EVs in cerebral feeding ar...
もっと見る詳細説明
Extracellular vesicles (EVs) are small lipid bilayer-enclosed vesicles that are widely secreted by almost all types of cells into the extracellular microenvironment. They carry biomolecules such as proteins, lipids, mRNA, and miRNA, and play important roles in intercellular communication and disease regulation. Due to their stability and specificity, EVs have become a research hotspot for the diagnosis and prognosis ...もっと見る
公式タイトル
Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions
疾患名
Subarachnoid Aneurysm Hemorrhage破裂していない頭蓋内動脈瘤その他の研究識別子
- DBCR-EV-p
- 25K218-001
NCT番号
開始日
2025-07-29
最終更新日
2026-02-27
終了予定日
2026-06
目標参加者数
120
試験の種類
観察研究
状況
募集中
キーワード
extracellular vesicles
blood
subarachnoid hemorrhage
intracranial aneurysm
blood
subarachnoid hemorrhage
intracranial aneurysm
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
Patients with ruptured intracranial aneurysms Patients with intracranial aneurysms who have suffered subarachnoid hemorrhage (CT-confirmed diagnosis of bleeding) need to be treated with endovascular surgeries. The blood sample collection during the surgery for hemorrhagic cases must occur within 3 days of symptom onset. | 該当なし |
Patients with unruptured intracranial aneurysms Patients with intracranial aneurysms without subarachnoid hemorrhage need to be treated with endovascular surgeries. | 該当なし |
主要評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Proteomics of extracellular vesicles (EVs) derived from different blood circulatory regions | During neurointerventional procedures under general anesthesia, 5 mL of blood will be collected from the patient's femoral vein, internal jugular vein, and internal carotid artery. After centrifugation to obtain plasma, extracellular vesicles will be extracted for proteomic detection and analysis. | From enrollment to the end of treatment at 7 days |
参加アシスタント
適格基準
対象年齢
成人
試験の最低年齢
18 Years
対象性別
全て
- 1. Aged between 18 and 60 years, regardless of gender; 2. Diagnosed with intracranial aneurysm confirmed by MRA, CTA, or DSA; 3. Patients with aneurysmal subarachnoid hemorrhage must have CT imaging evidence of hemorrhage, and blood collection must occur within 3 days of symptom onset; 4. Scheduled to undergo neurointerventional surgery for intracranial aneurysm under general anesthesia, with the procedure starting between 8:00 AM and 12:00 PM; 5. Willing to comply with the study protocol and data collection procedures; 6. Able to understand and sign the informed consent form.
- 1. Patients with a pre-onset (in hemorrhagic cases) or preoperative (in non-hemorrhagic cases) Modified Rankin Scale (MRS) score ≥ 2; 2. Presence of other neurological disorders such as Parkinson's disease, Alzheimer's disease, cerebral infarction, brain tumors, epilepsy, etc.; 3. Presence of other systemic diseases such as diabetes, coronary artery disease, cancer, infections, hematological diseases, or severe metabolic disorders that may significantly affect the evaluation of blood EVs; 4. History of severe hepatic or renal dysfunction (ALT > 3 times the upper limit of normal; creatinine > 225 μmol/L); 5. Patients who cannot tolerate anesthesia, anticoagulant therapy, or who have coagulation disorders; 6. History of severe allergic reactions to contrast agents; 7. Pregnant women; 8. Patients participating in other clinical trials who have not yet completed follow-up.
The First Hospital of Jilin University試験中央連絡先
連絡先: Zheng Wan, Medical Doctor， MD, 86-18743059601, [email protected]
1 1カ国の場所
Jilin
First Hospital of Jilin University, Changchun, Jilin, 130000, China
Zheng Wan, M.D., 連絡先, 86-18743059601, [email protected]
募集中